IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.052
AS - Asia 3.144
EU - Europa 2.535
SA - Sud America 346
AF - Africa 94
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 10.186
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.961
CN - Cina 1.603
SG - Singapore 637
IE - Irlanda 500
UA - Ucraina 384
HK - Hong Kong 356
FI - Finlandia 296
DE - Germania 282
VN - Vietnam 243
BR - Brasile 240
RU - Federazione Russa 238
FR - Francia 218
IT - Italia 193
SE - Svezia 152
GB - Regno Unito 138
IN - India 76
CA - Canada 44
ZA - Sudafrica 37
AR - Argentina 36
BD - Bangladesh 35
MX - Messico 34
PK - Pakistan 31
NL - Olanda 28
PL - Polonia 26
IQ - Iraq 24
JP - Giappone 21
EC - Ecuador 18
CO - Colombia 16
BE - Belgio 15
TR - Turchia 14
SA - Arabia Saudita 13
ES - Italia 11
ID - Indonesia 11
VE - Venezuela 11
JO - Giordania 10
MY - Malesia 10
PY - Paraguay 10
AT - Austria 9
LT - Lituania 9
PH - Filippine 8
TN - Tunisia 8
AU - Australia 7
CL - Cile 7
MA - Marocco 7
MU - Mauritius 7
EU - Europa 6
KE - Kenya 6
NP - Nepal 6
UZ - Uzbekistan 6
AL - Albania 5
CZ - Repubblica Ceca 5
EG - Egitto 5
CH - Svizzera 4
DZ - Algeria 4
GA - Gabon 4
GR - Grecia 4
NG - Nigeria 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
IL - Israele 3
IR - Iran 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
PA - Panama 3
RO - Romania 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LV - Lettonia 2
LY - Libia 2
OM - Oman 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
HU - Ungheria 1
JE - Jersey 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 10.176
Salva come PNG Salva come JPEG
Città #
Chandler 548
Dublin 500
Jacksonville 470
Hong Kong 352
Nanjing 352
Singapore 323
Ashburn 297
Dallas 291
San Jose 284
Beijing 250
Boardman 189
Lauterbourg 167
Nanchang 135
Hebei 116
Los Angeles 116
Princeton 112
Shenyang 109
Lawrence 108
Medford 102
Wilmington 102
Changsha 99
New York 97
Ann Arbor 84
Ho Chi Minh City 82
Jiaxing 69
Helsinki 64
Tianjin 62
Hanoi 55
Hangzhou 54
Munich 42
Buffalo 39
Milan 38
Shanghai 38
Woodbridge 38
Moscow 34
Orem 34
Redondo Beach 34
Santa Clara 32
Johannesburg 29
Warsaw 22
Council Bluffs 21
Tokyo 20
Turku 20
Rome 17
Norwalk 16
San Francisco 16
São Paulo 16
Verona 16
Brussels 15
Chennai 15
Rawalpindi 15
Toronto 15
Des Moines 14
Fairfield 13
Nuremberg 13
Pavia 13
Da Nang 12
Falkenstein 12
Manchester 12
Seattle 12
The Dalles 12
Auburn Hills 11
Mexico City 11
Montreal 11
Baghdad 10
Frankfurt am Main 10
Hải Dương 10
Stockholm 10
Amman 9
Boston 9
Brooklyn 9
Florence 9
Guayaquil 9
Jinan 9
Kunming 9
Phoenix 9
Poplar 9
Atlanta 8
Denver 8
Guangzhou 8
New Delhi 8
Ningbo 8
Pune 8
Rio de Janeiro 8
Riyadh 8
Zhengzhou 8
Amsterdam 7
Genoa 7
Haiphong 7
Istanbul 7
London 7
Taizhou 7
Chicago 6
Falls Church 6
Kuala Lumpur 6
Lanzhou 6
Phủ Lý 6
Tappahannock 6
Vienna 6
Xi'an 6
Totale 6.600
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 185
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 178
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 155
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 142
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 141
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 141
Blast phase of essential thrombocythemia: A single center study. 137
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 135
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 134
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 129
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 128
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 127
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 127
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 125
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 120
A gain-of-function mutation of JAK2 in myeloproliferative disorders 120
Clinical Predictors of Outcome in MPN. 119
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 119
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 115
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 115
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 114
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 114
Looking for CALR mutations in familial myeloproliferative neoplasms 110
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 109
JAK2 (V617F) mutation in healthy individuals 108
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 108
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 106
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 106
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 105
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 104
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 104
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 104
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 104
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 103
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 102
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 101
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 100
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 100
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 100
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 98
Leukemia risk models in primary myelofibrosis: an International Working Group study. 97
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 96
Clinical relevance of JAK2 (V617F) mutant allele burden 95
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 93
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 92
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 91
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 91
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 90
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 90
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 89
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 88
PDGFRB disease: right diagnosis to prolong survival 88
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 87
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 87
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 87
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 87
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 85
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 85
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 85
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 85
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 84
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 84
How I treat polycythemia vera. 84
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 84
New generation small-molecule inhibitors in myeloproliferative neoplasms 84
Leucemia mieloide cronica e sindromi mieloproliferative croniche 83
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 83
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 83
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 82
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 81
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 81
How to manage polycythemia vera 80
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 80
Myeloproliferative Neoplasms 79
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 79
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 78
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 76
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 76
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 76
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 75
Mutational status of myeloproliferative neoplasms. 74
RBC-transfusion guidelines update 74
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 74
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 74
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 73
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 73
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 72
What are RBC-transfusion-dependence and -independence? 72
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 72
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 72
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 71
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 71
Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi 70
Ruxolitinib and survival improvement in patients with myelofibrosis 70
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 69
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection 68
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. 68
Disease anticipation in familial myeloproliferative neoplasms. 67
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy 66
It is time to change thrombosis risk assessment for PV and ET? 66
Totale 9.608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.685
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.685
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021211 0 0 0 0 0 0 0 0 0 96 94 21
2021/2022493 11 6 11 6 19 11 6 29 21 17 82 274
2022/20231.573 168 96 18 149 150 180 2 102 632 11 32 33
2023/2024537 79 92 16 48 34 157 3 33 4 11 15 45
2024/20251.427 29 127 36 39 40 66 43 117 335 34 229 332
2025/20263.312 280 335 413 347 355 237 663 134 336 212 0 0
Totale 10.299